Ensoma

We recently got together at our annual winter party to celebrate each other and what we are building here at Ensoma. Check out some highlights of our memorable night! ??

At Ensoma, we are committed to a better future for patients, each other, and the community. Realizing our vision is personal. On #EmployeeAppreciationDay, we are grateful for our incredible team's work each day to push beyond today’s possible in genomic medicines, and the open, collaborative and driven environment they cultivate here at Ensoma.

Rare diseases are more common than you realize, and their impact on patients and families is #MoreThanYouCanImagine. Yesterday, 300+ Boston Seaport biotech members walked for the 300 million people whose lives have been altered by a rare disease and for better, equitable care. A sincere thank you to all who made #SeaportForRare a success in honor of #RareDiseaseDay!

This month, we served lunch and connected with patients and families at the AstraZeneca Hope Lodge in Boston. The Hope Lodge serves as a "home away from home" for patients and caregivers while going through outpatient cancer treatment. We were honored to spend time at the lodge and be a part of their incredible mission.

We are pleased to announce that the FDA has granted both rare pediatric disease and #orphandrug designations to our lead program, EN-374, for the treatment of X-linked chronic granulomatous disease (#XCGD). CGD is a rare, severe genetic disorder that significantly impairs the immune system, leaving patients vulnerable to recurring, severe bacterial and fungal infections. This often leads to dysregulated inflammation and serious complications. We plan to submit an IND for EN-374 in the first half of this year. VP of Clinical Development Andrew Dietz, MD, MSCR shares insight below into what this exciting milestone means for Ensoma. Read more here. https://lnkd.in/eFCTp94x

Today, we had the opportunity to hear about the career journeys of team members Elinor Shin, our SVP of Legal & IP and Anxhela Kole, our Director of Downstream Process Development, in honor of International Day of Women & Girls in Science. Today serves as a reminder both of how far our industry has come, and the strides we continue to make towards the advancement of #WomenInScience.

A note from?our CEO Jim Burns: At Ensoma, we firmly stand by the values of Diversity, Equity, and Inclusion (#DEI) because we believe acceptance and respect for all people is a fundamental human right. As a biotechnology company committed to advancing the future of medicine, we know that creating an inclusive and respectful environment drives innovation, fosters productivity, and enables us to deliver better therapies for all patients. Our mission to make genetic medicine more accessible is grounded in our belief that everyone deserves the opportunity to live a healthy, fulfilling life free from discrimination. DEI is at the heart of who we are—it's in our DNA, and it fuels the work we do every day.

The American Cancer Society estimates there will be over 2 million new cancer diagnoses in the U.S. this year. We need new treatments that raise the bar in both efficacy and patient experience. Today, our logo is turned upside down for #WorldCancerDay in honor of those whose worlds have been turned upside down by #cancer.

Ensoma team members are on the ground in San Francisco connecting with our industry and #genetherapy community peers at #JPM25 as we head into an exciting year of progressing our pipeline programs in chronic granulomatous disease, #sicklecelldisease and immunooncology. Here's to a productive and impactful week!

#JPM25 is quickly approaching, and Ensoma leaders look forward to heading to the west coast for a week of connections and discussions on the latest in the #genetherapy space. See you there!